Researchers assembled a newly curated collection of nasal bacterial strains and carried out systematic pairwise interaction analyses, testing how diverse S. aureus strains compete or cooperate with other members of the nasal microbiota. The experiments revealed that nasal species strongly modulate S. aureus growth, and that these effects are both strain-specific and community-specific.

The modulation was observed in vitro and confirmed in gnotobiotic mice, germ-free animals colonized with defined bacterial communities. This dual approach allowed the team to link laboratory-measured interactions to colonization outcomes in a living host, strengthening the case that nutrient exchange shapes who carries the pathogen.

Nutrient-dependent interactions emerged as key drivers of these relationships. In one striking example, synthetic bacterial communities supplied tyrosine, an amino acid that a particular S. aureus strain could not make for itself. With tyrosine provided by its neighbors, the auxotrophic strain proliferated; without supportive communities, its growth was compromised.

To gauge how widespread this dependency might be, the researchers screened a large collection of S. aureus strains. Roughly 8 percent showed tyrosine dependency, and colonization by these strains was impaired in the absence of communities able to provide the amino acid, indicating that the interaction has broader relevance beyond a single laboratory isolate.

The findings reveal distinct metabolic adaptations that allow S. aureus to exploit specific features of resident nasal communities. Rather than acting as a lone invader, the pathogen appears embedded in complex interspecies networks of cooperation and competition that influence whether colonization succeeds in the human nose.

While microbial cooperation and competition are well documented in environmental and intestinal microbial communities, their impact on pathogen colonization within the nasal microbiome had remained largely unknown. This study addresses that gap by applying the same ecological principles to the anterior nares, the nasal niche where S. aureus carriage occurs.

The authors suggest that these insights may inform microbiome-editing strategies aimed at displacing S. aureus from the nasal niche, since supportive communities can enable auxotrophic strains to persist in that environment.

The work, published open access in Microbiome, underscores that a pathogen’s success in a host niche can hinge on the metabolic generosity of its microbial neighbors, a factor that varies from strain to strain and from community to community.

Subject of Research: How amino acid availability shapes strain- and community-specific interactions between Staphylococcus aureus and the nasal microbiota

Article Title: Amino acid availability influences Staphylococcus aureus interaction with the nasal microbiota in a strain- and community-specific manner

Article References: Camus, L., Franz, J., Gerlach, D., Lange, A., Power, J. J., Navarro-Díaz, M., Stahl, J., Krismer, B., Rapp, J., Bilici, K., Otto, M., Klages, L. J., Starostin, V., Ham, S., Kalinowski, J., Angenent, L. T., Link, H., & Heilbronner, S. (2026). Amino acid availability influences Staphylococcus aureus interaction with the nasal microbiota in a strain- and community-specific manner. Microbiome, 14(1), Article 237. https://doi.org/10.1186/s40168-026-02563-x

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02563-x

Keywords: Staphylococcus aureus, nasal microbiota, amino acids, tyrosine, auxotrophy, microbiome, bacterial interactions, colonization, gnotobiotic mice, metabolism, Amino, acid

The study screened adult ICU patients by rectal culture at admission and weekly from July 2022 through August 2025. Rectal CRE colonization was identified in 287 of 3,221 ICU admissions, or 8.9%. Colonization was present at admission in 88 cases (30.7%) and acquired during the ICU stay in 199 (69.3%). Sixteen infections were detected on the colonization date and evaluated separately, leaving 271 admissions for the primary analysis of infection occurring after colonization.

For the risk analysis, time zero was defined as the first documented CRE colonization date. The researchers used competing-risk methods to estimate cumulative incidence, treating ICU death and live ICU discharge before infection as competing events. No evaluated factor was independently associated with subsequent infection in the Fine-Gray model. Prior colistin exposure was borderline but not statistically significant, with a subdistribution hazard ratio of 1.53, a 95% confidence interval of 0.99–2.37 and p = 0.057.

Mortality was higher among patients who developed subsequent infection than among those who did not: 71.2% versus 55.4% (p = 0.007). This was an observed association in a retrospective cohort and does not establish that subsequent infection caused the higher mortality. The findings are limited by the single-center design, retrospective data and the screened adult ICU population, and the available report is an abstract of an accepted article subject to later revision rather than a full assessment of the study.

Subject of Research: Prevalence, timing, outcomes and risk factors for subsequent CRE infection after rectal colonization in adult ICU patients

Article Title: Rectal colonization with Carbapenem-resistant Enterobacterales in intensive care unit patients: prevalence, clinical outcomes, and risk of subsequent infection

Article References: Yüce Yıldırım, D., Şenol, G., Yiş, R., & Gülfidan, Ö. G. (2026). Rectal colonization with Carbapenem-resistant Enterobacterales in intensive care unit patients: prevalence, clinical outcomes, and risk of subsequent infection. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14445-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14445-6

Keywords: CRE colonization, rectal culture, intensive care units, subsequent infection, carbapenem resistance, Enterobacterales, cumulative incidence, Fine-Gray model, retrospective cohort, patient mortality, Rectal, colonization

The answer, according to the team led by hematologist Cristina Tecchio, is a qualified no. Rectal colonization with multidrug-resistant organisms, or MDROs, was detected in 35 percent of the transplant recipients, yet not a single patient died of an MDRO-related infection within the first 100 days after transplantation. That zero infection-related mortality is striking, because gut colonization with resistant bacteria has repeatedly been linked in other studies to deadly bloodstream infections and poorer survival in transplant recipients. The Verona data suggest that the danger is real but manageable, provided clinicians know who is carrying what and act on that knowledge quickly.

The study was retrospective and longitudinal, reviewing hospital records of patients transplanted at the Verona hematology unit between April 2019 and April 2025. All patients were screened for MDROs by rectal swab at hospital admission and weekly during every hospitalization, from induction chemotherapy onward. The microbiology behind the screening is technically demanding: swabs were streaked onto selective media designed to flush out extended-spectrum beta-lactamase-producing Enterobacterales, carbapenemase-producing strains, and vancomycin-resistant enterococci. Carbapenemase production was confirmed with rapid biochemical tests, and enzyme types were identified with an immuno-chromatographic assay detecting NDM, OXA-48, KPC, VIM, and IMP-like carbapenemases. Clonality was assessed with an infrared spectroscopy system that clusters bacterial isolates by their spectral fingerprints, allowing the team to determine whether bacteria recovered months apart were the same strain.

That technical rigor paid off in an unexpected discovery. Of the 44 MDRO strains detected across the cohort, 70.5 percent had already been isolated in the same patients during previous hospital stays for induction or consolidation chemotherapy. In other words, most of the resistant bacteria found around the time of transplant were not new arrivals; they were old tenants that had persisted through weeks of treatment, sometimes disappearing from screening only to reappear during the profound neutropenia that follows the conditioning regimen. The researchers confirmed this persistence in two patients using clonality analysis and PCR, which detected the same ESBL resistance genes, blaCTX-M1 in one case and blaSHV in the other, in isolates recovered before and after transplantation.

This finding carries a sober clinical implication: a single negative rectal swab does not reliably mean the gut has been cleared. Negative results may reflect intermittent carriage, bacterial loads below the detection threshold of culture-based screening, sampling variability, or temporary suppression of the colonizing population by antibiotics. The Verona team argues that a patient’s longitudinal microbiological history, including the species, resistance phenotype, and date of every prior isolation, may be more informative than the most recent screening result. They call for that information to be systematically transferred between referring hematology units and transplant centers and incorporated into pre-transplant risk assessment.

The epidemiology of colonization itself was revealing. Enterobacterales, a family of Gram-negative gut bacteria that includes Escherichia coli and Klebsiella pneumoniae, accounted for 72.7 percent of all MDROs, mostly ESBL-producing strains. Nearly half of colonized patients, 45.7 percent, were already positive at hospital admission for the transplant, while the rest became positive during hospitalization, within 33 days after the infusion. Notably, four patients colonized with ESBL-producing E. coli or K. pneumoniae later shifted their resistance patterns, acquiring carbapenem resistance, a change that narrows treatment options considerably. The researchers acknowledge that routine fluoroquinolone prophylaxis, given until neutrophil engraftment, may have exerted selective pressure on the intestinal microbiota, favoring the persistence and expansion of resistant Enterobacterales.

Colonization did translate into more infections, even if those infections proved survivable. Bloodstream infections caused by MDROs occurred in 20 percent of carriers compared with only 3.1 percent of non-carriers, a statistically significant difference, and MDRO-related urinary tract infections occurred in 20 percent of carriers versus 6 percent of non-carriers. Seven of the nine patients who developed MDRO-related bloodstream infections were rectal carriers, underscoring the gut as the likely reservoir. Yet none of these infections was life-threatening, no patient required intensive care, and there were no carbapenem-resistant bloodstream infections at all. The team attributes this tempered severity to targeted empirical antibiotics: when fever struck, colonized patients were treated according to their known resistance profiles rather than with a one-size-fits-all regimen, and therapy was continued for at least 14 days after an MDRO-related bloodstream infection, withdrawn only after two consecutive negative blood cultures.

Survival analysis told a subtler story. Overall survival was significantly lower in MDRO carriers at univariate analysis, with estimated survival of 53.4 percent versus 80.6 percent beyond 24 months, and carriers had 2.37 times the risk of death compared with non-carriers. But when the researchers adjusted for disease status in a multivariable Cox model, the association between colonization and survival dissolved, with only active disease at transplant, which carried a 5.11-fold higher hazard of death, remaining significant. Transplant-related mortality showed a similar pattern, a trend toward significance at univariate analysis that vanished after adjustment. The interpretation offered by the authors is that MDRO colonization may primarily reflect cumulative healthcare exposure, repeated antimicrobial pressure, and greater underlying disease and treatment complexity, rather than acting as an independent determinant of mortality.

The study has clear limitations that the authors confront directly. It was retrospective, single-center, and relatively small, with few outcome events, rendering the multivariable analyses exploratory and potentially underpowered. Clonality of recurrent strains could be confirmed in only two cases. The center’s bundle of supportive practices, including weekly surveillance, standardized prophylaxis, protective isolation, and a low-microbial diet, was implemented as routine care and not evaluated independently, so its individual contribution to the favorable outcomes cannot be isolated. Multicenter studies with larger cohorts are needed to validate the findings.

Even so, the message resonates at a time when antimicrobial resistance is climbing worldwide and transplant medicine is expanding. The Verona results suggest that the prognostic weight of gut MDRO colonization in acute leukemia transplant recipients is not fixed; it can be lightened by systematic surveillance that extends beyond admission screening, by awareness of each patient’s past colonization history, and by the prompt use of targeted antibiotics followed by rapid de-escalation when cultures come back negative. In a field where conflicting studies have left clinicians uncertain about how much to fear resistant gut bacteria, this Italian cohort offers a pragmatic middle path: the bacteria are common, the infections are more frequent in carriers, but with vigilance and tailored therapy, the deadliest outcomes may be preventable.

Subject of Research: Infectious Diseases

Article Title: Rectal colonization with multidrug-resistant organisms in adult acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective, longitudinal, single-center study

Article References: Tamellini, E., Bonetto, C., Mazzariol, A., Mazzaferri, F., Diani, E., Tolio, F., Pagnin, S., Vatteroni, A., Crema, A., Schena, A., & Tecchio, C. (2026). Rectal colonization with multidrug-resistant organisms in adult acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective, longitudinal, single-center study. Frontiers in Cellular and Infection Microbiology, 16, Article 1902132. https://doi.org/10.3389/fcimb.2026.1902132

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1902132

Keywords: multidrug-resistant organisms, stem cell transplantation, acute leukemia, antimicrobial resistance, bloodstream infection, rectal colonization, infection surveillance, Rectal, colonization, multidrug-resistant, organisms, adult

The research team, led by Anh Ly, Anika Sehgal, and colleagues at the University of Calgary’s Cumming School of Medicine, set out to explore an underexamined dimension of the opioid epidemic: the perspectives of the physicians who actually prescribe opioids and care for Indigenous patients with opioid use disorder. While previous scholarship has documented risk factors for opioid-related harm among Indigenous peoples, including overprescribing, trauma rooted in ongoing colonization, systemic racism, socioeconomic disadvantage, and barriers to culturally safe health services, the role of healthcare providers and the systems they operate within has received comparatively little attention. The new study addresses that gap directly.

Methodologically, the study relied on in-person, open-ended, semi-structured interviews with a convenience sample of 13 physicians working across a striking range of practice environments: urban centers, rural communities, and on-reserve settings. This diversity matters, because the structural conditions surrounding opioid care differ dramatically depending on geography and jurisdiction. The researchers employed an inductive thematic analysis, with transcripts independently examined and coded by two research associates using an iterative coding process designed to surface overarching themes and their associated sub-themes. The study received ethics approval from the Conjoint Health Research Ethics Board at the University of Calgary, and all participants provided written informed consent before taking part.

Four predominant themes emerged from the analysis. First, physicians emphasized the fundamental importance of maintaining relationships with their patients, positioning continuity and trust as the bedrock of effective care for opioid use disorder. Second, participants called for increased attention to pain management strategies, pointing to a tension at the heart of opioid medicine: the need to treat genuine suffering while avoiding the harms of overprescribing. Third, the physicians described the considerable challenges and goals inherent in a de-prescribing approach, the deliberate, careful process of tapering patients off opioids when clinically appropriate. Fourth, and perhaps most sobering, they described the structural and social contexts that shape care for opioid use disorder, from colonial legacies to poverty and systemic inequity.

That fourth theme carries the study’s most consequential implications. Participants explicitly highlighted the influence of colonization, intergenerational trauma, poverty, and systemic inequities on patient outcomes. Yet they also candidly expressed the difficulty of addressing these forces within the confines of a standard clinical encounter. A physician may recognize that a patient’s opioid use is entangled with housing instability, food insecurity, or the accumulated weight of historical and ongoing discrimination, but the fifteen-minute appointment slot offers few tools to respond. The study captures this dissonance between awareness and action, showing that physicians are not blind to structural determinants of health; they are often simply unequipped to act on them.

The interviews also revealed substantial variation in physicians’ experience, knowledge, and comfort when working with Indigenous patients. This inconsistency is significant because it means the quality of care a patient receives may depend heavily on which physician they happen to see. Some providers bring deep cultural understanding and trauma-informed practice; others lack training in the history and ongoing realities that shape Indigenous patients’ interactions with the healthcare system. The participants themselves pointed to this unevenness as a problem, and several offered suggestions for improving medical education curricula, arguing that better preparation during training could reduce the variability that patients currently experience.

Practical constraints compounded these knowledge gaps. Physicians described being squeezed by clinical schedules that left too little time for the complex, trust-dependent work that opioid use disorder care demands. Resource availability varied widely across settings, and access to services, particularly in rural and on-reserve communities, was frequently limited. A physician who wants to connect a patient with culturally safe addiction treatment, mental health support, or social services may find that those services simply do not exist nearby, or that waitlists stretch for months. In such circumstances, the prescription becomes the path of least resistance, not because clinicians are careless, but because the system offers few alternatives.

The de-prescribing theme deserves particular attention. Reducing or discontinuing opioids in patients who have been on them long-term is clinically delicate work, requiring careful tapering schedules, monitoring for withdrawal and relapse, and robust alternative pain management options. The physicians in this study described de-prescribing as a goal, but one fraught with obstacles: patients with untreated chronic pain, limited access to multidisciplinary pain services, and the risk that abrupt changes could push patients toward illicit and far more dangerous drug supplies. In the context of a toxicity crisis driven increasingly by fentanyl-contaminated street drugs, poorly managed de-prescribing can be as dangerous as overprescribing, a nuance the study’s participants clearly understood.

Taken together, the findings point toward what the authors describe as the necessity for fundamental changes in how care for Indigenous peoples with opioid use disorder is conceptualized and delivered. Physicians, the study concludes, function within a disjointed system influenced by persistent colonial dynamics, unequal resources, and inconsistent training. Progress, the researchers argue, will depend on approaches that engage patients’ social realities, strengthen clinical relationships, and confront the structural factors that shape health outcomes. In other words, the prescription problem is not merely a prescribing problem; it is a systems problem, and it demands systems-level solutions.

The study arrives at a moment when Canada, like the United States, is grappling with the devastating legacy of both aggressive opioid marketing in the 1990s and the subsequent tightening of prescribing that pushed many patients toward illicit drugs. For Indigenous communities, these national dynamics intersect with a distinct history: residential schools, the Sixties Scoop, jurisdictional ambiguities in health service delivery, and ongoing racism within healthcare institutions, all documented contributors to health inequity. What this new research adds is the physician’s-eye view of that intersection, showing that even providers who recognize these forces feel constrained by the structures around them. The message for policymakers is clear: supporting Indigenous patients with opioid use disorder means investing in culturally safe services, reforming medical education, giving clinicians the time and resources to build real relationships, and dismantling the structural inequities that no individual prescription can fix.

Subject of Research: Physicians' perspectives on opioid prescribing and structural factors shaping opioid use disorder care for Indigenous patients in Canada

Article Title: What’s behind the pain? Exploring physicians’ views on prescribing practices and structural factors that contribute to opioid use among Indigenous patients

Article References: Ly, A., McInnes, A., Annan, J., Crowshoe, L. L., Henderson, R., & Sehgal, A. (2026). What’s behind the pain? Exploring physicians’ views on prescribing practices and structural factors that contribute to opioid use among Indigenous patients. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15610-y

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15610-y

Keywords: Indigenous health, opioid use disorder, opioid prescribing, physicians, health inequities, pain management, de-prescribing, colonization, intergenerational trauma, qualitative research, primary care, Canada